As these treatments become more popular, theyre changing how the industry approaches chronic diseasebringing both fresh opportunities but also new challenges
doi: 10.1016/S0006-8993(00)02741-4 224 BomfimTRForny-GermanoLSathlerLBBrito-MoreiraJHouzelJCDeckerHet al
GLP-1 Pills No injections, no procedure, may reduce appetite and cravings, easier entry point for many patients
Food & Drug Administration, 2020 Available from: Collins L, Costello RA
But in the beginning of last year, we, we said, no, it has to be for a diabetes prescription. -Senior Human Resources Leader, large services organization The use of GLP-1 agonists was higher than expected for many large employers including for over half (59%) of employers over 5,000 workers Since then, many larger employers covering GLP-1 agonists for weight loss reported higher than expected use of the medications and significant impacts on their prescription spending
These include studies evaluating semaglutide and dulaglutide in individuals with AUD, with primary outcomes measuring changes in drinking patterns, craving intensity, and alcohol-related consequences
